All-trans Retinoic Acid, and Arsenic +/- Idarubicin

NCT00413166 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Acute Promyelocytic Leukemia

Interventions

DRUG: All-Trans Retinoic Acid (ATRA)
DRUG: Arsenic Trioxide (ATO)
DRUG: Idarubicin
DRUG: Gemtuzumab Ozogamicin

Sponsor

M.D. Anderson Cancer Center